Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.58
-0.86 (-1.36%)
At close: Jan 16, 2026, 4:00 PM EST
63.33
+0.75 (1.20%)
After-hours: Jan 16, 2026, 6:04 PM EST
Cytokinetics Employees
Cytokinetics had 498 employees as of December 31, 2024. The number of employees increased by 75 or 17.73% compared to the previous year.
Employees
498
Change (1Y)
75
Growth (1Y)
17.73%
Revenue / Employee
$175,122
Profits / Employee
-$1,509,928
Market Cap
7.65B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 498 | 75 | 17.73% |
| Dec 31, 2023 | 423 | 14 | 3.42% |
| Dec 31, 2022 | 409 | 156 | 61.66% |
| Dec 31, 2021 | 253 | 69 | 37.50% |
| Dec 31, 2020 | 184 | 28 | 17.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CYTK News
- 7 days ago - Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Cytokinetics: Small Label Differences With Big Commercial Stakes - Seeking Alpha
- 4 weeks ago - Cytokinetics Wins FDA Nod For Heart Drug Myqorzo - Benzinga
- 4 weeks ago - Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript - Seeking Alpha
- 4 weeks ago - US FDA approves Cytokinetics' heart disease drug - Reuters
- 4 weeks ago - Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms - GlobeNewsWire
- 4 weeks ago - Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire